Relapsed and/or Refractory Multiple Myeloma Clinical Trial
Official title:
A Prospective, Multicenter, Observational Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
The purpose of this study is to investigate the real world effectiveness and safety of ixazomib in combination with lenalidomide and dexamethasone (IRd) in patients with relapsed and/or refractory multiple myeloma (RRMM), under conditions of standard medical care. In addition, an exploratory study of biomarkers will be conducted.
The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have relapsed and/or refractory multiple myeloma (RRMM) under the conditions of standard medical care. This study is a non-interventional (observational), domestic, multicenter, prospective study in patients with RRMM. This study will look at the effectiveness and safety of ixazomib in combination with lenalidomide and dexamethasone in Japanese patients with RRMM as standard medical care. In addition, an exploratory study of biomarkers will be conducted in this study. The study will enroll approximately 300 patients. All participants will receive Ixazomib + Lenalidomide + Dexamethasone (IRd) therapy as standard medical care. This multi-center trial will be conducted in Japan. The overall time of observational period in this study will be 36 months. For each participant, the observation period will be from the start of IRd therapy until either 24 months after the enrollment date of the final patient to enroll, or until death or withdrawal of consent, whichever is earlier. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03140943 -
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05066022 -
A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma
|
N/A | |
| Recruiting |
NCT06182696 -
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03715478 -
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
|
Phase 1/Phase 2 | |
| Completed |
NCT02917941 -
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
|
Phase 2 | |
| Not yet recruiting |
NCT03903406 -
Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
|
||
| Completed |
NCT03242460 -
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
|
Phase 2 | |
| Terminated |
NCT03836053 -
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05719701 -
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05297240 -
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
|
||
| Terminated |
NCT04272775 -
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
|
Phase 1 | |
| Not yet recruiting |
NCT06351644 -
ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04392648 -
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
|
Phase 1 | |
| Active, not recruiting |
NCT01632150 -
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT02831686 -
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
|
Phase 1 | |
| Recruiting |
NCT06153251 -
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00882063 -
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Terminated |
NCT04017130 -
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT03416374 -
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
|
Phase 4 | |
| Recruiting |
NCT05486975 -
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
|
Early Phase 1 |